This unit is the final to be studied in the Graduate Certificate in Dermatology Nursing. The learning has been scaffolded to build from foundational to advanced concepts for the nurse whom is working or would like to work in the dermatology speciality. Topics include advanced patient management strategies, ethical dilemmas and evaluation of care. Nurses will also explore the future of dermatology and the burden of psychodermatological health.
There is a 40 hour clinical placement included in this unit of study.
|Advanced Concepts of Dermatology Nursing|
|Unit of study code||313|
|Availability||Graduate Certificate in Dermatology Nursing|
|Pre-requisite||311 – Foundational Concepts of Dermatology Nursing|
|Hours of study||150|
|Clinical placement information||
There is a compulsory 40 hours clinical placement for this unit of study.
Anyone applying for an ACN course that includes a clinical placement must provide evidence of compliance documents at the time of application.
Applications for enrolment will not be progressed until all relevant documentation has been received by customer services.
Each Australian state and territory has its own clinical placement documentation requirements. Please view our Clinical Placement Information page, then click on the tab for your particular state or territory for information on specific requirements.
Individual placement providers may need additional documentation. If you are required to provide this then you will be contacted by the clinical placement officer following enrolment.
ACN negotiates with health care facilities to secure clinical placements. ACN will make every effort to secure clinical placements within the timeframe indicated in the course outline, however applicants are advised that provision and location of clinical placements is dependent on the availability of placements within the health facility.
As placements are difficult to secure, once confirmed these cannot be negotiated unless there is unforeseen extenuating circumstances. Applicants are not to arrange their own clinical placements with a clinical facility under any circumstances. ACN reserves the right to change clinical placements if necessary.
|Recognition of Prior Learning (RPL) for clinical placement||
Students can be granted recognition of prior learning (RPL) for clinical placement if:
Documentation that will be accepted as evidence:
Please note there is no charge for this application of RPL and students will still have to complete the online learning units of study and the associated assessment items.
|Prescribed texts||Nicol N., 2016, Dermatologic Nursing Essentials: A core curriculum|
|Co-ordinated by||Jamie-May Newman
Intended learning outcomes for this subject/program
After completing this subject, the learner will be able to:-
Type of assessment
Note the completed assessment item (e.g. Assessment 1: Online discussion)
(% of total marks)
When assessed – academic week
(e.g. Week 8)
|Theme 1: Advanced patient management strategies||a) critically analyse the specialist role of the dermatology nurse and the implications for future practice||Assessment 1: Online discussions x 2||10%||3, 8|
|Theme 2: Ethical dilemmas||b) critically reflect upon the advanced concepts of dermatology nursing management to inform clinical practice within the multidisciplinary team||Assessment 2: Reflective essay||40%||5|
|Theme 3: Infection prevention and control||c) examine the impact of psychodermatological nursing practice on patient and social outcomes||Assessment 3: Case analysis||50%||10|
|Theme 4: Evaluation of care||d) discuss safe skin health promotion across high risk populations|
|Theme 5: The future of dermatology nursing||e) evaluate the effectiveness of treatments used for skin conditions in relation to ongoing care and quality of life.|
Advanced Concepts of Dermatology Nursing (313) is a Tier 4 unit.
|Tiers||2020 Member price (10% discount)||2020 Non-member price||2021 Member price (10% discount)||2021 Non-member price|
*Fees are subject to change without notice.
Development of this subject was sponsored by Novartis